ScreenerHero

MAIA MAIA Biotechnology, Inc.

AMEX · US · Healthcare · Biotechnology · maiabiotech.com
1.180USD-0.84%Mkt Cap: 72.86M $P/E: —

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap72.86M USD
Enterprise Value44.79M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.40M USD
Revenue/Share—
Last Price1.180 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)1.07
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.50
EPS (TTM)-0.62
EPS (Forward)1.11
52W Range
0.870013% of range3.190
52W High3.190 USD
52W Low0.8700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-942.65%
ROA-230.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.84M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-18.93%
Net Debt-27.60M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio4.51
Quick Ratio4.41
Book Value/Sh0.34 USD
Cash/Share0.45 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.00 USD
Upside (mean)+916.9%
Target Range10.00 USD – 14.00 USD
10.00+916.9% to mean14.00
# Analysts2
Ownership
Shares Out.61.74M
Float55.30M
Insiders14.41%
Institutions21.91%
Short Interest
Short Ratio4.5d
Short % Float3.76%
Short % Out.3.45%
Shares Short2.10M
Short (prev mo.)2.75M
Technical
SMA 501.321 (-10.7%)
SMA 2001.490 (-20.8%)
Beta0.28
S&P 52W Chg15.77%
Avg Vol (30d)582.79K
Avg Vol (10d)716.92K
Technical Indicators
RSI (14)39.3
MACD-0.0471
MACD Signal-0.0386
MACD Hist.-0.0085
BB Upper1.444 USD
BB Middle1.268 USD
BB Lower1.091 USD
BB Width27.93%
ATR (14)0.0662 USD
Vol Ratio (20d)0.53x